The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, regulation and clinical research. However, without a biological rationale for these disorders, drug development has stagnated. The recently EU-funded PRISM project aims to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of better treatments. By combining clinical data sets from major worldwide disease cohorts and by applying innovative technologies to deeply phenotype stratified patient groups, we will define a set of quantifiable biological parameters for social withdrawal and cognitive deficits common to Schizophrenia (SZ), Major Depression (MD), and Alzheimer’s Disease (AD). These studies aim to provide new classification and assessment tools for social and cognitive performance across neuropsychiatric disorders, clinically relevant substrates for treatment development, and predictive, preclinical animal systems. With patients and regulatory agencies, we seek to provide clear routes for the future translation and regulatory approval for new treatments and provide solutions to the growing public health challenges of psychiatry and neurology.

神经精神疾病的当前分类学允许采取务实的方法进行治疗选择，调节和临床研究。但是，由于没有这些疾病的生物学原理，药物开发停滞了。最近由欧盟资助的PRISM项目旨在开发一种定量的生物学方法来理解和分类神经精神疾病，以加速发现和开发更好的治疗方法。通过结合来自全球主要疾病队列的临床数据集，并将创新技术应用于表型分层的患者群体，我们将为精神分裂症（SZ），严重抑郁症（MD）常见的社交退缩和认知缺陷定义一套可量化的生物学参数，和阿尔茨海默氏病（AD）。这些研究旨在为神经精神疾病的社会和认知表现，治疗开发的临床相关底物以及可预测的临床前动物系统提供新的分类和评估工具。我们与患者和监管机构合作，为未来的翻译和新疗法的监管批准提供清晰的途径，并为日益增长的精神病学和神经病学公共卫生挑战提供解决方案。